Cancer prevention in HIV-infected populations

Semin Oncol. 2016 Feb;43(1):173-188. doi: 10.1053/j.seminoncol.2015.09.011. Epub 2015 Sep 8.

Abstract

People living with human immunodeficiency virus (HIV) are living longer since the advent of effective combined antiretroviral therapy (cART). While cART substantially decreases the risk of developing some cancers, HIV-infected individuals remain at high risk for Kaposi sarcoma, lymphoma, and several solid tumors. Currently HIV-infected patients represent an aging group, and malignancies have become a leading cause of morbidity and mortality. Tailored cancer-prevention strategies are needed for this population. In this review we describe the etiologic agents and pathogenesis of common malignancies in the setting of HIV, as well as current evidence for cancer prevention strategies and screening programs.

Keywords: AIDS-related lymphoma; HIV; HPV vaccines; Kaposi sarcoma; Neoplasms.

Publication types

  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Anti-Retroviral Agents / therapeutic use*
  • Coinfection
  • Early Detection of Cancer
  • Epstein-Barr Virus Infections / complications
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • HIV Infections / virology
  • Hepatitis B, Chronic / complications
  • Humans
  • Neoplasms / diagnosis
  • Neoplasms / etiology*
  • Neoplasms / prevention & control*
  • Papillomavirus Infections / complications
  • Papillomavirus Vaccines / therapeutic use
  • Smoking / adverse effects
  • Smoking Cessation
  • Sunlight / adverse effects
  • Sunscreening Agents / therapeutic use
  • Viremia / immunology

Substances

  • Anti-Retroviral Agents
  • Papillomavirus Vaccines
  • Sunscreening Agents